Released : 13th December 2018
UK -- December 13, 2018
In preparation for the planned withdrawal of the United Kingdom (UK) from the European Union (EU) (Brexit) on 29 March 2019, we are taking steps to mitigate risk and minimize disruption to the delivery of our products to our customers and patients.
The future trade relationship between the UK and the EU remains uncertain. There are still many unknowns relating to Brexit and the impact it may have on the Medical Device industry. At this time, we are actively preparing for various Brexit scenarios, assessing risks and potential impact on our business. This includes carrying out a risk-based assessment of our entire business processes including customs, regulatory, tariff and supply chain and establishing risk mitigation plans in each area. We are also working closely with regulatory bodies to identify solutions to ensure our products and therapies can reach patients who need them with minimal disruption.
We believe Brexit will not have a material impact on our relationships with our customers and partners, and as always, our focus is on providing best-in-class therapies. We remain committed to ensuring continued access to our technologies in the UK, Europe and the rest of the world.